Final analysis from KEYNOTE-585 (NCT03221426) revealed that event-free survival (EFS) was not significantly improved, ...

Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy ...

The FDA approved tepylute, a ready-to-dilute formulation of an existing treatment for breast and ovarian adenocarcinoma.

Nikhil Khushalani, MD, discussed a phase 3 study investigating fianlimab plus cemiplimab vs nivolumab and relatlimab for the ...

Douglas B. Johnson, MD, MSCI, offers a comprehensive exploration of the nuances for using neoadjuvant therapy, addressing ...

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, discussed how he would have approached a patient with anemia from ...

Recent approvals herald novel strategies for addressing advanced or metastatic breast cancer with ESR1 mutations.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

During a Case-Based Roundtable® event, Deepak Kilari, MD, discussed with participants how updated data on frontline regimens ...

The Oncology Brothers and Mark A. Lewis, MD, review recent updates from the COLLISION study that were presented at the 2024 ...

Elizabeth Logers, MD, PhD, discusses the implications of ovarian toxicity on female patients of reproductive age being ...

Secondary malignancies following CAR T-cell therapy have been a known risk, but an FDA investigation and call for labeling ...